title: 'Fracture incidence after 3 years of aromatase inhibitor therapy'.
authors.affiliation: Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, KU Leuven, Leuven Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine, KU Leuven, Leuven Center for Metabolic Bone Diseases, University Hospitals Leuven, Leuven michael.laurent@med.kuleuven.be.
authors.forename: M R
authors.initials: MR
authors.lastname: Laurent
authors.affiliation: Division of Gynaecological Oncology, Department of Oncology, KU Leuven, Leuven Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven.
authors.forename: P
authors.initials: P
authors.lastname: Neven
authors.affiliation: Center for Metabolic Bone Diseases, University Hospitals Leuven, Leuven Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Vanderschueren
mesh_terms: D047072:Aromatase Inhibitors / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced*; D006801:Humans
chemical_list: D047072:Aromatase Inhibitors